SCHEMBL791232

SCHEMBL791232

COC(=O)C1CCC(=O)CC1

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.46
TP53 P04637 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.43
CHRNB2 P17787 2/20 0.41
CHRNA4 P43681 2/20 0.41
CHRNB4 P30926 1/20 0.41
CHRNA3 P32297 1/20 0.41
CHRNA7 P36544 1/20 0.41
ALDH1A1 P00352 1/20 0.40
POLB P06746 1/20 0.40
GAA P10253 1/20 0.40
KDM4E B2RXH2 1/20 0.39
CYP1A2 P05177 1/20 0.39
HIF1A Q16665 1/20 0.39
PPM1B O75688 1/20 0.38
PTPN1 P18031 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene SCHEMBL11701928 0.96 BRD4 (0.43) BRD4TP53SMN1; SMN2CHRNB2CHRNA4
SCHEMBL9633492 0.92 SMN1; SMN2 (0.46) BRD4TP53SMN1; SMN2CHRNB2CHRNA4
SCHEMBL8408089 0.88 TP53 (0.44) BRD4TP53SMN1; SMN2CHRNB2CHRNA4
SCHEMBL8410901 0.88 TP53 (0.44) BRD4TP53SMN1; SMN2CHRNB2CHRNA4
SCHEMBL8410904 0.88 TP53 (0.44) BRD4TP53SMN1; SMN2CHRNB2CHRNA4
SCHEMBL8408087 0.88 TP53 (0.44) BRD4TP53SMN1; SMN2CHRNB2CHRNA4
SCHEMBL17014460 0.87 BRD4 (0.47) BRD4TP53SMN1; SMN2CHRNB2CHRNA4
SCHEMBL4868550 0.87 BRD4 (0.47) BRD4TP53SMN1; SMN2CHRNB2CHRNA4
SCHEMBL1139285 0.87 BRD4 (0.47) BRD4TP53SMN1; SMN2CHRNB2CHRNA4
SCHEMBL13245966 0.83 BRD4 (0.38) BRD4TP53SMN1; SMN2CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 523 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117865889-A Synthesis method of benzisoquinoline compound 山东省药学科学院 2024-04-12 CN claimed
CN-114426497-A Preparation method of trans-4-aminocyclohexanecarboxylic acid hydrochloride 泰州精英化成医药科技有限公司 2022-05-03 CN claimed
CN-109678788-B 1, 2-diaryl indole, derivative and synthetic method thereof 湘潭大学 2021-05-04 CN claimed
CN-109678788-A A kind of 1,2- diaryl indoles, derivative and its synthetic method 湘潭大学 2019-04-26 CN claimed
CN-105001296-B A kind of nitric oxide donator type dexamethasone and preparation method and purposes 中国人民解放军第三军医大学 2016-11-30 CN claimed
EP-0257727-B1 PROCESS FOR PREPARING CYCLOHEXANONECARBOXYLIC ACID COMPOUNDS MITSUI TOATSU CHEMICALS, Inc. (JP) 1989-08-30 EP claimed
US-4785132-A CATALYTIC HYDROGENATION OF HYDROXYBENZOIC ACIDS MITSUI TOATSU CHEMICALS, INCORPORATED (JP) 1988-11-15 US claimed
EP-0257727-A1 Process for preparing cyclohexanonecarboxylic acid compounds MITSUI TOATSU CHEMICALS, Inc. (JP) 1988-03-02 EP claimed
US-12583839-B2 PD-L1 antagonist compound ADLAI NORTYE BIOPHARMA CO., LTD. (CN) 2026-03-24 US disclosed
EP-4121421-B1 BIARYL DERIVATIVES AS YAP/TAZ-TEAD PROTEIN-PROTEIN INTERACTION INHIBITORS NOVARTIS AG (CH) 2026-03-11 EP disclosed
US-20250388593-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2025-12-25 US disclosed
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors Jubilant Epicore LLC (US) 2025-11-25 US disclosed
EP-4650348-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR Mitsubishi Tanabe Pharma Corporation (JP) 2025-11-19 EP disclosed
EP-3455204-B1 CYCLOPROPYL-AMIDE COMPOUNDS AS DUAL LSD1/HDAC INHIBITORS Jubilant Epicore LLC (US) 2025-10-29 EP disclosed
US-4629805-A Alkyl substituted and unsubstituted para-carboalkoxy cyclohexanones and organoleptic uses thereof INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 1986-12-16 US disclosed
US-4614831-A FROM PHENOL DERIVATIVES INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 1986-09-30 US disclosed
US-4537704-A Alkyl substituted and unsubstituted para-carboalkoxy cyclohexanones and organoleptic uses thereof INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) 1985-08-27 US disclosed
US-4370323-A 2-Cyanoaziridinyl-(1)-2-substituted-aziridinyl-(1)-methanes BOEHRINGER MANNHEIM GMBH (DE) 1983-01-25 US disclosed
US-3953425-A Azepine indanyl and tetralin butyrophenones THE UPJOHN COMPANY (US) 1976-04-27 US disclosed
US-3948939-A 9-Acyl-1,2,3,4-tetrahydrocarbazole-3 and 4-carboxylic acids STERLING DRUG INC. (US) 1976-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12479797-B2 Cyclopropyl-amide compounds as dual LSD1/HDAC inhibitors HDAC1, HDAC11, HDAC2 BRD4 362/4885TP53 440/4885SMN1; SMN2 1068/4885
US-20250388593-A1 CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR CRBN, CUL1, CBL BRD4 1339/4885TP53 1819/4885SMN1; SMN2 566/4885
US-12583839-B2 PD-L1 antagonist compound CD274, PDCD1LG2, PDCD1 BRD4 842/4885TP53 927/4885SMN1; SMN2 3268/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.